Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Details for Australian Patent Application No. 2004268381 (hide)

Owner Novartis AG

Inventors Manning, Donald

Agent Davies Collison Cave

Pub. Number AU-B-2004268381

PCT Pub. Number WO2005/020968

Priority 60/537,378 16.01.04 US; 0320637.2 03.09.03 GB

Filing date 2 September 2004

Wipo publication date 10 March 2005

Acceptance publication date 18 June 2009

International Classifications

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

Event Publications

9 March 2006 PCT application entered the National Phase

  PCT publication WO2005/020968 Priority application(s): WO2005/020968

18 June 2009 Application Accepted

  Published as AU-B-2004268381

15 October 2009 Standard Patent Sealed

31 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004268382-Use of modified cyclosporins for the treatment of HCV disorders

2004268380-Method of stabilizing ascorbyl phosphate and salts thereof